A benchmarking system to spark companies to action - innovation that fuels new deal flow and growth pipelines
Click image to view it in full size
The global Non-Invasive Prenatal Testing (NIPT) market is moving from a nascent to growth phase. Ongoing consolidations are largely focused on distribution and marketing of NIPTs to expand access and coverage, followed by product development and commercialization agreements. In a sector of more than 20 global industry participants, Frost & Sullivan independently plotted the top 10 NIPT companies in this Frost Radar™ analysis: Natera, Inc., (NTRA), Illumina, Inc., (ILMN), LabCorp (LH), BGI Genomics Co., Ltd (BGI), Roche (RO), Yourgene Health PLC. (YGEN), Quest Diagnostics (DGX), Eurofins Scientific (EUR), PerkinElmer, Inc., (PKI) and Cradle Genomics, that are truly innovating and best positioned to deliver high value to customers in the future. Natera emerged as a leader on the Growth and Innovation indexes of the Frost Radar™. As a global market leader in NIPT, the Panorama test is empowered by the largest prospective, multi-site study ever performed in NIPT that demonstrates market-leading performance of the test in a real-world setting. Illumina and LabCorp sit high on the Growth and Innovation index of the Frost Radar™. Considered as pioneers, the three industry participants demonstrate significant leadership in the evidence of samples processed, superior technology strategy roadmap, and multi-faceted customer engagement strategy.
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.